TY - JOUR
T1 - Subchronic toxicity of lunasin targeted extract (ET-Lun) from soybean seed (Glycine max (L.) Merr.)
T2 - Perspective from liver histopathology, SGOT, and SGPT levels in Sprague Dawley rats
AU - Rusdi, Numlil Khaira
AU - Yuliana, Weri Lia
AU - Purwaningsih, Erni Hernawati
AU - Hestiantoro, Andon
AU - Kusmardi, Kusmardi
N1 - Funding Information:
The authors are grateful to the Directorate of Research and Development, University of Indonesia for funding the 2020/2021 doctoral grant with the contract NKB-590/UN2.RST/HKP.05.00/2020 and BA-076/UN2. RST/PPM.00.03.01/2021.
Publisher Copyright:
© 2021 Phcogj.Com.
PY - 2021/12
Y1 - 2021/12
N2 - Background: Lunasin Targeted Extract (ET-Lun) has a pharmacology effect in inhibiting inflammation by decreasing COX-2 and iNOS expression. ET-Lun could increase apoptosis and decrease dysplasia (p > 0,05). In addition, ET-Lun could decrease EGFR expression in breast cancer rats. The acute toxicity showed ET-Lun has LD50 more than 5000 mg/kg BW and was practically non-toxic. Objective: this study aimed to determine the subchronic toxicity of ET-Lun. Methods: Male and female Sprague Dawley rats (n=40) were divided into 4 groups, the control group and treatment group ET-Lun dose of 250 mg/Kg BW, 500 mg/kg BW, and 750 mg/kg BW. The ET-Lun was administered for 90 days. On the 91st day, the animals were dissected and examined for SGOT-SGPT levels, liver histopathology, and diameter of the central vein. Results: The SGOT-SGPT levels showed no significant difference between the treatment group and the control group (p > 0.05). On microscopic observation, there was no change or damage to the liver of rats in each group. The diameter of the central vein of the rat liver shows no significant difference between the control and treatment groups. Conclusion: The ET-Lun does not produce adverse effects in liver rats after subchronic treatment.
AB - Background: Lunasin Targeted Extract (ET-Lun) has a pharmacology effect in inhibiting inflammation by decreasing COX-2 and iNOS expression. ET-Lun could increase apoptosis and decrease dysplasia (p > 0,05). In addition, ET-Lun could decrease EGFR expression in breast cancer rats. The acute toxicity showed ET-Lun has LD50 more than 5000 mg/kg BW and was practically non-toxic. Objective: this study aimed to determine the subchronic toxicity of ET-Lun. Methods: Male and female Sprague Dawley rats (n=40) were divided into 4 groups, the control group and treatment group ET-Lun dose of 250 mg/Kg BW, 500 mg/kg BW, and 750 mg/kg BW. The ET-Lun was administered for 90 days. On the 91st day, the animals were dissected and examined for SGOT-SGPT levels, liver histopathology, and diameter of the central vein. Results: The SGOT-SGPT levels showed no significant difference between the treatment group and the control group (p > 0.05). On microscopic observation, there was no change or damage to the liver of rats in each group. The diameter of the central vein of the rat liver shows no significant difference between the control and treatment groups. Conclusion: The ET-Lun does not produce adverse effects in liver rats after subchronic treatment.
KW - Liver
KW - Lunasin
KW - SGOT
KW - SGPT
KW - Soybean
KW - Subchronic toxicity
UR - http://www.scopus.com/inward/record.url?scp=85120333876&partnerID=8YFLogxK
U2 - 10.5530/PJ.2021.13.175
DO - 10.5530/PJ.2021.13.175
M3 - Article
AN - SCOPUS:85120333876
SN - 0975-3575
VL - 13
SP - 1384
EP - 1388
JO - Pharmacognosy Journal
JF - Pharmacognosy Journal
IS - 6
ER -